9 results on '"Shangwen Pan"'
Search Results
2. Bioinformatic analysis identifies potential biomarkers and therapeutic targets of septic-shock-associated acute kidney injury
- Author
-
You Shang, Xiaobo Yang, Yuan Yu, Shangwen Pan, Huaqing Shu, Yun Tang, and Jiqian Xu
- Subjects
Biology ,QH426-470 ,Bioinformatics ,GZMB ,Sepsis ,03 medical and health sciences ,0302 clinical medicine ,Septic shock ,Bioinformatic analysis ,microRNA ,medicine ,Genetics ,Humans ,Protein Interaction Maps ,KEGG ,Oligonucleotide Array Sequence Analysis ,030304 developmental biology ,0303 health sciences ,Research ,Gene Expression Profiling ,Acute kidney injury ,Computational Biology ,General Medicine ,PTX3 ,medicine.disease ,Shock, Septic ,Gene Ontology ,Case-Control Studies ,030220 oncology & carcinogenesis ,Differentially expressed genes ,Biomarkers ,SLPI - Abstract
Background Sepsis and septic shock are life-threatening diseases with high mortality rate in intensive care unit (ICU). Acute kidney injury (AKI) is a common complication of sepsis, and its occurrence is a poor prognostic sign to septic patients. We analyzed co-differentially expressed genes (co-DEGs) to explore relationships between septic shock and AKI and reveal potential biomarkers and therapeutic targets of septic-shock-associated AKI (SSAKI). Methods Two gene expression datasets (GSE30718 and GSE57065) were downloaded from the Gene Expression Omnibus (GEO). The GSE57065 dataset included 28 septic shock patients and 25 healthy volunteers and blood samples were collected within 0.5, 24 and 48 h after shock. Specimens of GSE30718 were collected from 26 patients with AKI and 11 control patents. AKI-DEGs and septic-shock-DEGs were identified using the two datasets. Subsequently, Gene Ontology (GO) functional analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, and protein-protein interaction (PPI) network analysis were performed to elucidate molecular mechanisms of DEGs. We also evaluated co-DEGs and corresponding predicted miRNAs involved in septic shock and AKI. Results We identified 62 DEGs in AKI specimens and 888, 870, and 717 DEGs in septic shock blood samples within 0.5, 24 and 48 h, respectively. The hub genes of EGF and OLFM4 may be involved in AKI and QPCT, CKAP4, PRKCQ, PLAC8, PRC1, BCL9L, ATP11B, KLHL2, LDLRAP1, NDUFAF1, IFIT2, CSF1R, HGF, NRN1, GZMB, and STAT4 may be associated with septic shock. Besides, co-DEGs of VMP1, SLPI, PTX3, TIMP1, OLFM4, LCN2, and S100A9 coupled with corresponding predicted miRNAs, especially miR-29b-3p, miR-152-3p, and miR-223-3p may be regarded as promising targets for the diagnosis and treatment of SSAKI in the future. Conclusions Septic shock and AKI are related and VMP1, SLPI, PTX3, TIMP1, OLFM4, LCN2, and S100A9 genes are significantly associated with novel biomarkers involved in the occurrence and development of SSAKI.
- Published
- 2021
3. Clinical characteristics and risk factors associated with ICU-acquired infections in sepsis: A retrospective cohort study
- Author
-
Yajun He, Jiqian Xu, Xiaopu Shang, Xiangzhi Fang, Chenggang Gao, Deyi Sun, Lu Yao, Ting Zhou, Shangwen Pan, Xiaojing Zou, Huaqing Shu, Xiaobo Yang, and You Shang
- Subjects
Microbiology (medical) ,Intensive Care Units ,Infectious Diseases ,Organ Dysfunction Scores ,Risk Factors ,Sepsis ,Immunology ,Humans ,Microbiology ,Retrospective Studies - Abstract
Intensive care unit (ICU)-acquired infection is a common cause of poor prognosis of sepsis in the ICU. However, sepsis-associated ICU-acquired infections have not been fully characterized. The study aims to assess the risk factors and develop a model that predicts the risk of ICU-acquired infections in patients with sepsis.MethodsWe retrieved data from the Medical Information Mart for Intensive Care (MIMIC) IV database. Patients were randomly divided into training and validation cohorts at a 7:3 ratio. A multivariable logistic regression model was used to identify independent risk factors that could predict ICU-acquired infection. We also assessed its discrimination and calibration abilities and compared them with classical score systems.ResultsOf 16,808 included septic patients, 2,871 (17.1%) developed ICU-acquired infection. These patients with ICU-acquired infection had a 17.7% ICU mortality and 31.8% in-hospital mortality and showed a continued rise in mortality from 28 to 100 days after ICU admission. The classical Systemic Inflammatory Response Syndrome Score (SIRS), Sequential Organ Failure Assessment (SOFA), Oxford Acute Severity of Illness Score (OASIS), Simplified Acute Physiology Score II (SAPS II), Logistic Organ Dysfunction Score (LODS), Charlson Comorbidity Index (CCI), and Acute Physiology Score III (APS III) scores were associated with ICU-acquired infection, and cerebrovascular insufficiency, Gram-negative bacteria, surgical ICU, tracheostomy, central venous catheter, urinary catheter, mechanical ventilation, red blood cell (RBC) transfusion, LODS score and anticoagulant therapy were independent predictors of developing ICU-acquired infection in septic patients. The nomogram on the basis of these independent predictors showed good calibration and discrimination in both the derivation (AUROC = 0.737; 95% CI, 0.725–0.749) and validation (AUROC = 0.751; 95% CI, 0.734–0.769) populations and was superior to that of SIRS, SOFA, OASIS, SAPS II, LODS, CCI, and APS III models.ConclusionsICU-acquired infections increase the likelihood of septic mortality. The individualized prognostic model on the basis of the nomogram could accurately predict ICU-acquired infection and optimize management or tailored therapy.
- Published
- 2022
4. Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study
- Author
-
Shangwen Pan, Lianguo Ruan, You Shang, Yongran Wu, Lu Chen, Lehao Ren, Ke Hong, Jiqian Xu, Chaolin Huang, Jiancheng Zhang, and Xiaobo Yang
- Subjects
Male ,0301 basic medicine ,China ,medicine.medical_specialty ,Convalescent plasma ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,030106 microbiology ,Immunology ,Convalescent plasma therapy ,Antibodies, Viral ,Virus ,03 medical and health sciences ,Medical microbiology ,Virology ,Internal medicine ,Humans ,Medicine ,COVID-19 Serotherapy ,Aged ,Retrospective Studies ,SARS-CoV-2 ,business.industry ,Immunization, Passive ,COVID-19 ,RNA ,Retrospective cohort study ,Length of Stay ,Middle Aged ,Viral Load ,030104 developmental biology ,RNA, Viral ,Molecular Medicine ,Female ,business ,Viral load ,Research Article ,Prolonged positivity - Abstract
Convalescent plasma therapy has been implemented in a few cases of severe coronavirus disease 2019. No report about convalescent plasma therapy in treating patients with prolonged positivity of SARS-CoV-2 RNA has been published. In this study, we conducted a retrospective observational study in 27 patients with prolonged positivity of SARS-CoV-2 RNA, the clinical benefit of convalescent plasma therapy were analyzed. qRT-PCR test of SARS-CoV-2 RNA turned negative (≤ 7 days) in a part of patients (early negative group, n = 15) after therapy, others (late negative group, n = 12) turned negative in more than 7 days. Pulmonary imaging improvement was confirmed in 7 patients in early negative group and 8 in late negative group after CP therapy. Viral load decreased in early negative group compared with late negative group at day 3, 5, 7 after implementing convalescent plasma therapy. Patients in early negative group had a shorter median length of hospital stay. In conclusion, convalescent plasma therapy might help eliminate virus and shorten length of hospital stay in patients with prolonged positivity of SARS-CoV-2 RNA.
- Published
- 2020
- Full Text
- View/download PDF
5. Dynamic Changes of Antibodies to SARS-CoV-2 in COVID-19 Patients at Early Stage of Outbreak
- Author
-
You Shang, Peng Zhou, Yongran Wu, Hong Liu, Yaxin Wang, Yin Yuan, Shangwen Pan, Shiying Yuan, Shunan Ruan, Shuzhen Wang, Ruiting Li, Jiancheng Zhang, Huaqing Shu, and Yaqi Ouyang
- Subjects
Adult ,Male ,0301 basic medicine ,China ,medicine.medical_specialty ,030106 microbiology ,Immunology ,Enzyme-Linked Immunosorbent Assay ,Antibodies, Viral ,medicine.disease_cause ,COVID-19 Serological Testing ,Serology ,Young Adult ,03 medical and health sciences ,Medical microbiology ,Virology ,medicine ,Humans ,Seroconversion ,Pandemics ,Antibody ,Aged ,Retrospective Studies ,Coronavirus ,Aged, 80 and over ,biology ,SARS-CoV-2 ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,COVID-19 ,Correction ,Outbreak ,Retrospective cohort study ,Middle Aged ,Nucleocapsid Proteins ,Coronavirus disease 2019 (COVID-19) ,030104 developmental biology ,Immunoglobulin M ,Immunoglobulin G ,biology.protein ,Molecular Medicine ,Female ,business ,Contact tracing ,Research Article - Abstract
The coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has spread around the world with high mortality. To diagnose promptly and accurately is the vital step to effectively control its pandemic. Dynamic characteristics of SARS-CoV-2-specific antibodies which are important for diagnosis of infection have not been fully demonstrated. In this retrospective, single-center, observational study, we enrolled the initial 131 confirmed cases of COVID-19 at Jin-Yin-Tan Hospital who had at least one-time antibody tested during their hospitalization. The dynamic changes of IgM and IgG antibodies to SARS-CoV-2 nucleocapsid protein in 226 serum samples were detected by ELISA. The sensitivities of IgM and IgG ELISA detection were analyzed. Result showed that the sensitivity of the IgG ELISA detection (92.5%) was significantly higher than that of the IgM (70.8%) (P
- Published
- 2020
- Full Text
- View/download PDF
6. Resolvin D1 attenuates mechanical stretch-induced pulmonary fibrosis via epithelial-mesenchymal transition
- Author
-
Hai-Rong Xiao, Haifa Xia, Lu Qin, Wei Xiong, Lin Chen, Jiqian Xu, You Shang, Yaxin Wang, Min Liu, Shengnan Li, Lisha Hu, Yiyi Yang, Shangwen Pan, Shu-Nan Cui, Limin Song, Ting Zhou, and Shanglong Yao
- Subjects
Male ,0301 basic medicine ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,ARDS ,Epithelial-Mesenchymal Transition ,Docosahexaenoic Acids ,Physiology ,Pulmonary Fibrosis ,medicine.medical_treatment ,Acute respiratory distress ,Cell Line ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Physiology (medical) ,Internal medicine ,Pulmonary fibrosis ,medicine ,Animals ,Humans ,Epithelial–mesenchymal transition ,Mechanical ventilation ,Respiratory Distress Syndrome ,business.industry ,Cell Biology ,medicine.disease ,Respiration, Artificial ,Resolvin d1 ,Mice, Inbred C57BL ,Disease Models, Animal ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cardiology ,Stress, Mechanical ,business - Abstract
Mechanical ventilation-induced pulmonary fibrosis plays an important role in the high mortality rate of acute respiratory distress syndrome (ARDS). Resolvin D1 (RvD1) displays potent proresolving activities. Epithelial-mesenchymal transition (EMT) has been proved to be an important pathological feature of lung fibrosis. This study aimed to investigate whether RvD1 can attenuate mechanical ventilation-induced lung fibrosis. Human lung epithelial (BEAS-2B) cells were pretreated with RvD1 for 30 min and exposed to acid for 10 min before being subjected to mechanical stretch for 48 h. C57BL/6 mice were subjected to intratracheal acid aspiration followed by mechanical ventilation 24 h later (peak inspiratory pressure 22 cmH2O, positive end-expiratory pressure 2 cmH2O, and respiratory rate 120 breaths/min for 2 h). RvD1 was injected into mice for 5 consecutive days after mechanical ventilation. Treatment with RvD1 significantly inhibited mechanical stretch-induced mesenchymal markers (vimentin and α-smooth muscle actin) and stimulated epithelial markers (E-cadherin). Tert-butyloxycarbonyl 2 (BOC-2), a lipoxin A4 receptor/formyl peptide receptor 2 (ALX/FPR2) antagonist, is known to inhibit ALX/FPR2 function. BOC-2 could reverse the beneficial effects of RvD1. The antifibrotic effect of RvD1 was associated with the suppression of Smad2/3 phosphorylation. This study demonstrated that mechanical stretch could induce EMT and pulmonary fibrosis and that treatment with RvD1 could attenuate mechanical ventilation-induced lung fibrosis, thus highlighting RvD1 as an effective therapeutic agent against pulmonary fibrosis associated with mechanical ventilation.
- Published
- 2019
- Full Text
- View/download PDF
7. A Systematic Review and Meta-Analysis Comparing Programmed Intermittent Bolus and Continuous Infusion as the Background Infusion for Parturient-Controlled Epidural Analgesia
- Author
-
Jiqian Xu, Jie Zhou, You Shang, Jie Liu, Shangwen Pan, Hai-Rong Xiao, and Shanglong Yao
- Subjects
Adult ,Anesthesia, Epidural ,0301 basic medicine ,Continuous infusion ,medicine.drug_class ,MEDLINE ,lcsh:Medicine ,Article ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Bolus (medicine) ,Randomized controlled trial ,Pregnancy ,law ,Humans ,Pain Management ,Medicine ,Infusions, Parenteral ,Anesthetics, Local ,lcsh:Science ,Pain Measurement ,Randomized Controlled Trials as Topic ,Labor, Obstetric ,Multidisciplinary ,business.industry ,Local anesthetic ,lcsh:R ,Analgesia, Patient-Controlled ,Labor pain ,Analgesia, Epidural ,Regimen ,030104 developmental biology ,Anesthesia ,Meta-analysis ,Analgesia, Obstetrical ,Female ,lcsh:Q ,business ,030217 neurology & neurosurgery - Abstract
The programmed intermittent epidural bolus (PIEB) technique offers multiple benefits over continuous epidural infusion (CEI), but controversy still exists when it is used in conjunction with a parturient-controlled epidural analgesia (PCEA) regimen. A systematic review and meta-analysis was thus conducted using the Medline, EMBASE, CENTRAL and Web of Science databases with the aim of identifying those randomized controlled trials (RCTs) that performed a comparison between PIEB and CEI in healthy parturients using a PCEA regimen with regard to the duration of labor, labor pain, anesthesia interventions, maternal satisfaction and main side effects. The data were analyzed using a random-effects model. Eleven eligible trials were included, in which 717 participants were allocated to the PIEB + PCEA group and 650 patients were allocated to the CEI + PCEA group. The rate of instrumental delivery, incidence of breakthrough pain, PCEA usage rates and local anesthetic usage were significantly reduced, the labor duration was statistically shorter, and the maternal satisfaction score was significantly improved in the PIEB + PCEA group compared with that in the CEI + PCEA group. There were no differences in the side effects between the two groups. The results of the present study suggest that the PIEB technique in conjunction with the PCEA regimen was more advantageous than CEI + PCEA, but additional studies should be conducted to consistently demonstrate an improvement in the maternal and fetal obstetric outcomes.
- Published
- 2019
- Full Text
- View/download PDF
8. The peak levels of highly sensitive troponin I predicts in-hospital mortality in COVID-19 patients with cardiac injury: a retrospective study
- Author
-
Xiaojing Zou, Jiqian Xu, You Shang, Dan Xu, Hong Qi, Qiongya Wang, Xiaobo Yang, Xin Zhao, Xia Li, Yin Yuan, Xing Zhou, Huaqing Shu, Yuan Yu, Hong Liu, Yaxin Wang, and Shangwen Pan
- Subjects
Male ,Heart Injury ,medicine.medical_specialty ,Heart Diseases ,030204 cardiovascular system & hematology ,Peak levels of troponin I ,Critical Care and Intensive Care Medicine ,Logistic regression ,Sensitivity and Specificity ,03 medical and health sciences ,0302 clinical medicine ,Predictive Value of Tests ,Internal medicine ,Troponin I ,medicine ,Humans ,030212 general & internal medicine ,Hospital Mortality ,Mortality ,Levels of troponin I at admission ,Aged ,Retrospective Studies ,Original Scientific Paper ,Receiver operating characteristic ,biology ,business.industry ,COVID-19 ,Retrospective cohort study ,General Medicine ,Middle Aged ,Troponin ,Confidence interval ,Cardiac injury ,Predictive value of tests ,biology.protein ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
AimsTo investigate the association between levels of highly sensitive troponin I (hs-troponin I) and mortality in novel coronavirus disease 2019 (COVID-19) patients with cardiac injury.Methods and resultsWe retrospectively reviewed the medical records of all COVID-19 patients with increased levels of hs-troponin I from two hospitals in Wuhan, China. Demographic information, laboratory test results, cardiac ultrasonographic findings, and electrocardiograms were collected, and their predictive value on in-hospital mortality was explored using multivariable logistic regression. Of 1500 patients screened, 242 COVID-19 patients were enrolled in our study. Their median age was 68 years, and (48.8%) had underlying cardiovascular diseases. One hundred and seventy-six (72.7%) patients died during hospitalization. Multivariable logistic regression showed that C-reactive protein (>75.5 mg/L), D-dimer (>1.5 μg/mL), and acute respiratory distress syndrome were risk factors of mortality, and the peak hs-troponin I levels (>259.4 pg/mL) instead of the hs-troponin I levels at admission was predictor of death. The area under the receiver operating characteristic curve of the peak levels of hs-troponin I for predicting in-hospital mortality was 0.79 (95% confidence interval, 0.73–0.86; sensitivity, 0.80; specificity, 0.72; P ConclusionOur results demonstrated that the risk of in-hospital death among COVID-19 patients with cardiac injury can be predicted by the peak levels of hs-troponin I during hospitalization and was significantly associated with oxygen supply-demand mismatch, inflammation, and coagulation.
- Published
- 2020
9. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study
- Author
-
Zhui Yu, Shiying Yuan, Xiaojing Zou, You Shang, Jia'an Xia, Huaqing Shu, Ting Yu, Yongran Wu, Jiqian Xu, Xiaobo Yang, Minghao Fang, Yuan Yu, Hong Liu, Yaxin Wang, Lu Zhang, and Shangwen Pan
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,China ,medicine.medical_specialty ,ARDS ,Critical Illness ,medicine.medical_treatment ,Pneumonia, Viral ,law.invention ,Betacoronavirus ,03 medical and health sciences ,0302 clinical medicine ,law ,medicine ,Humans ,030212 general & internal medicine ,Pandemics ,Aged ,Retrospective Studies ,Aged, 80 and over ,Mechanical ventilation ,Respiratory Distress Syndrome ,SARS-CoV-2 ,business.industry ,Incidence (epidemiology) ,Acute kidney injury ,COVID-19 ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Respiration, Artificial ,Intensive care unit ,Intensive Care Units ,Pneumonia ,Treatment Outcome ,030228 respiratory system ,Pneumothorax ,Emergency medicine ,Female ,Coronavirus Infections ,business - Abstract
Summary Background An ongoing outbreak of pneumonia associated with the severe acute respiratory coronavirus 2 (SARS-CoV-2) started in December, 2019, in Wuhan, China. Information about critically ill patients with SARS-CoV-2 infection is scarce. We aimed to describe the clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia. Methods In this single-centered, retrospective, observational study, we enrolled 52 critically ill adult patients with SARS-CoV-2 pneumonia who were admitted to the intensive care unit (ICU) of Wuhan Jin Yin-tan hospital (Wuhan, China) between late December, 2019, and Jan 26, 2020. Demographic data, symptoms, laboratory values, comorbidities, treatments, and clinical outcomes were all collected. Data were compared between survivors and non-survivors. The primary outcome was 28-day mortality, as of Feb 9, 2020. Secondary outcomes included incidence of SARS-CoV-2-related acute respiratory distress syndrome (ARDS) and the proportion of patients requiring mechanical ventilation. Findings Of 710 patients with SARS-CoV-2 pneumonia, 52 critically ill adult patients were included. The mean age of the 52 patients was 59·7 (SD 13·3) years, 35 (67%) were men, 21 (40%) had chronic illness, 51 (98%) had fever. 32 (61·5%) patients had died at 28 days, and the median duration from admission to the intensive care unit (ICU) to death was 7 (IQR 3–11) days for non-survivors. Compared with survivors, non-survivors were older (64·6 years [11·2] vs 51·9 years [12·9]), more likely to develop ARDS (26 [81%] patients vs 9 [45%] patients), and more likely to receive mechanical ventilation (30 [94%] patients vs 7 [35%] patients), either invasively or non-invasively. Most patients had organ function damage, including 35 (67%) with ARDS, 15 (29%) with acute kidney injury, 12 (23%) with cardiac injury, 15 (29%) with liver dysfunction, and one (2%) with pneumothorax. 37 (71%) patients required mechanical ventilation. Hospital-acquired infection occurred in seven (13·5%) patients. Interpretation The mortality of critically ill patients with SARS-CoV-2 pneumonia is considerable. The survival time of the non-survivors is likely to be within 1–2 weeks after ICU admission. Older patients (>65 years) with comorbidities and ARDS are at increased risk of death. The severity of SARS-CoV-2 pneumonia poses great strain on critical care resources in hospitals, especially if they are not adequately staffed or resourced. Funding None.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.